494 related articles for article (PubMed ID: 31710864)
21. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
[TBL] [Abstract][Full Text] [Related]
22. Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States.
Hess LM; Han Y; Zhu YE; Bhandari NR; Sireci A
BMC Cancer; 2021 Jan; 21(1):28. PubMed ID: 33402119
[TBL] [Abstract][Full Text] [Related]
23. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results.
Ueno M; Ikeda M; Sasaki T; Nagashima F; Mizuno N; Shimizu S; Ikezawa H; Hayata N; Nakajima R; Morizane C
BMC Cancer; 2020 Nov; 20(1):1105. PubMed ID: 33198671
[TBL] [Abstract][Full Text] [Related]
24. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
Drilon A; Fu S; Patel MR; Fakih M; Wang D; Olszanski AJ; Morgensztern D; Liu SV; Cho BC; Bazhenova L; Rodriguez CP; Doebele RC; Wozniak A; Reckamp KL; Seery T; Nikolinakos P; Hu Z; Oliver JW; Trone D; McArthur K; Patel R; Multani PS; Ahn MJ
Cancer Discov; 2019 Mar; 9(3):384-395. PubMed ID: 30487236
[No Abstract] [Full Text] [Related]
25. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
[TBL] [Abstract][Full Text] [Related]
26. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
27. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
[TBL] [Abstract][Full Text] [Related]
28. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
Brose MS; Worden FP; Newbold KL; Guo M; Hurria A
J Clin Oncol; 2017 Aug; 35(23):2692-2699. PubMed ID: 28613956
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Selpercatinib in
Drilon A; Oxnard GR; Tan DSW; Loong HHF; Johnson M; Gainor J; McCoach CE; Gautschi O; Besse B; Cho BC; Peled N; Weiss J; Kim YJ; Ohe Y; Nishio M; Park K; Patel J; Seto T; Sakamoto T; Rosen E; Shah MH; Barlesi F; Cassier PA; Bazhenova L; De Braud F; Garralda E; Velcheti V; Satouchi M; Ohashi K; Pennell NA; Reckamp KL; Dy GK; Wolf J; Solomon B; Falchook G; Ebata K; Nguyen M; Nair B; Zhu EY; Yang L; Huang X; Olek E; Rothenberg SM; Goto K; Subbiah V
N Engl J Med; 2020 Aug; 383(9):813-824. PubMed ID: 32846060
[TBL] [Abstract][Full Text] [Related]
30. Drug safety evaluation of lenvatinib for thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
[TBL] [Abstract][Full Text] [Related]
31. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers.
Suyama K; Iwase H
Cancer Control; 2018; 25(1):1073274818789361. PubMed ID: 30032643
[TBL] [Abstract][Full Text] [Related]
32. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509).
Capdevila J; Fazio N; Lopez C; Teulé A; Valle JW; Tafuto S; Custodio A; Reed N; Raderer M; Grande E; Garcia-Carbonero R; Jimenez-Fonseca P; Hernando J; Bongiovanni A; Spada F; Alonso V; Antonuzzo L; Spallanzani A; Berruti A; La Casta A; Sevilla I; Kump P; Giuffrida D; Merino X; Trejo L; Gajate P; Matos I; Lamarca A; Ibrahim T
J Clin Oncol; 2021 Jul; 39(20):2304-2312. PubMed ID: 33945297
[TBL] [Abstract][Full Text] [Related]
33. Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.
Huang Q; Schneeberger VE; Luetteke N; Jin C; Afzal R; Budzevich MM; Makanji RJ; Martinez GV; Shen T; Zhao L; Fung KM; Haura EB; Coppola D; Wu J
Mol Cancer Ther; 2016 Oct; 15(10):2521-2529. PubMed ID: 27496134
[TBL] [Abstract][Full Text] [Related]
34. RET fusion gene: translation to personalized lung cancer therapy.
Kohno T; Tsuta K; Tsuchihara K; Nakaoku T; Yoh K; Goto K
Cancer Sci; 2013 Nov; 104(11):1396-400. PubMed ID: 23991695
[TBL] [Abstract][Full Text] [Related]
35. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Finn RS; Ikeda M; Zhu AX; Sung MW; Baron AD; Kudo M; Okusaka T; Kobayashi M; Kumada H; Kaneko S; Pracht M; Mamontov K; Meyer T; Kubota T; Dutcus CE; Saito K; Siegel AB; Dubrovsky L; Mody K; Llovet JM
J Clin Oncol; 2020 Sep; 38(26):2960-2970. PubMed ID: 32716739
[TBL] [Abstract][Full Text] [Related]
36. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
37. RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients.
Sarfaty M; Moore A; Neiman V; Dudnik E; Ilouze M; Gottfried M; Katznelson R; Nechushtan H; Sorotsky HG; Paz K; Katz A; Saute M; Wolner M; Moskovitz M; Miller V; Elvin J; Lipson D; Ali S; Gutman LS; Dvir A; Gordon N; Peled N
Clin Lung Cancer; 2017 Jul; 18(4):e223-e232. PubMed ID: 28082048
[TBL] [Abstract][Full Text] [Related]
38. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
Cabanillas ME; Takahashi S
Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503).
Iwasa S; Okita N; Kuchiba A; Ogawa G; Kawasaki M; Nakamura K; Shoji H; Honma Y; Takashima A; Kato K; Hamaguchi T; Boku N; Yamada Y
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817132
[TBL] [Abstract][Full Text] [Related]
40. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer.
Cai W; Su C; Li X; Fan L; Zheng L; Fei K; Zhou C
Cancer; 2013 Apr; 119(8):1486-94. PubMed ID: 23378251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
